AU2005271513A1 - Use of N-desmethylclozapine to treat human neuropsychiatric disease - Google Patents

Use of N-desmethylclozapine to treat human neuropsychiatric disease Download PDF

Info

Publication number
AU2005271513A1
AU2005271513A1 AU2005271513A AU2005271513A AU2005271513A1 AU 2005271513 A1 AU2005271513 A1 AU 2005271513A1 AU 2005271513 A AU2005271513 A AU 2005271513A AU 2005271513 A AU2005271513 A AU 2005271513A AU 2005271513 A1 AU2005271513 A1 AU 2005271513A1
Authority
AU
Australia
Prior art keywords
clozapine
desmethylclozapine
ndmc
symptoms
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005271513A
Other languages
English (en)
Other versions
AU2005271513A2 (en
Inventor
Mark R. Brann
David M. Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acadia Pharmaceuticals Inc
Original Assignee
Acadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/913,117 external-priority patent/US20050085463A1/en
Priority claimed from US11/098,892 external-priority patent/US20050250767A1/en
Application filed by Acadia Pharmaceuticals Inc filed Critical Acadia Pharmaceuticals Inc
Publication of AU2005271513A1 publication Critical patent/AU2005271513A1/en
Publication of AU2005271513A2 publication Critical patent/AU2005271513A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2005271513A 2004-08-05 2005-08-04 Use of N-desmethylclozapine to treat human neuropsychiatric disease Abandoned AU2005271513A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10/913,117 2004-08-05
US10/913,117 US20050085463A1 (en) 2003-01-23 2004-08-05 Use of N-desmethylclozapine to treat human neuropsychiatric disease
US61755304P 2004-10-08 2004-10-08
US60/617,553 2004-10-08
US11/098,892 US20050250767A1 (en) 2003-01-23 2005-04-04 Use of N-desmethylclozapine to treat human neuropsychiatric disease
US11/098,892 2005-04-04
PCT/US2005/027645 WO2006017614A1 (en) 2004-08-05 2005-08-04 Use of n-desmethylclozapine to treat human neuropsychiatric disease

Publications (2)

Publication Number Publication Date
AU2005271513A1 true AU2005271513A1 (en) 2006-02-16
AU2005271513A2 AU2005271513A2 (en) 2006-02-16

Family

ID=35511003

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005271513A Abandoned AU2005271513A1 (en) 2004-08-05 2005-08-04 Use of N-desmethylclozapine to treat human neuropsychiatric disease

Country Status (5)

Country Link
EP (1) EP1778244A1 (enrdf_load_stackoverflow)
JP (1) JP2008509147A (enrdf_load_stackoverflow)
AU (1) AU2005271513A1 (enrdf_load_stackoverflow)
CA (1) CA2576153A1 (enrdf_load_stackoverflow)
WO (1) WO2006017614A1 (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004308955B2 (en) 2003-12-22 2011-08-04 Acadia Pharmaceuticals Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
KR20090013815A (ko) * 2006-05-04 2009-02-05 솔베이 파마슈티칼스 비. 브이 충동 조절 장애의 치료를 위한 무스카린 작용제
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
GB0708186D0 (en) * 2007-04-27 2007-06-06 Merck Sharp & Dohme Therapeutic compounds
US9018202B2 (en) * 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
CN106749219A (zh) * 2015-11-20 2017-05-31 江苏恩华药业股份有限公司 一种内酰胺类衍生物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ541014A (en) * 2003-01-23 2008-05-30 Acadia Pharm Inc Use of N-desmethylclozapine to treat schizophrenia while increasing the level of activity of a muscarinic receptor
WO2004073639A2 (en) * 2003-02-19 2004-09-02 Merck & Co. Inc. Treatment of psychosis with a muscarinic m1 receptor ectopic activator

Also Published As

Publication number Publication date
JP2008509147A (ja) 2008-03-27
EP1778244A1 (en) 2007-05-02
WO2006017614A1 (en) 2006-02-16
AU2005271513A2 (en) 2006-02-16
CA2576153A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
US20050085463A1 (en) Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20060194831A1 (en) Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20070275957A1 (en) Use of n-desmethylclozapine to treat human neuropsychiatric disease
Weiner et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine
EP1994932A1 (en) Use of N-desmethylclozapine to treat human psychosis
McElroy et al. Role of antiepileptic drugs in the management of eating disorders
Pahwa et al. New antipsychotic medications in the last decade
AU2006252708A1 (en) Methods and compositions for managing psychotic disorders
AU2021209279B2 (en) Therapeutic uses of L-4-chlorokynurenine
CN110167562A (zh) Dmpc、dmpg、dmpc/dmpg、lysopg和lysopc针对引起离子通道病的药物的保护作用
Ketter et al. Carbamazepine and oxcarbazepine
AU2005271513A1 (en) Use of N-desmethylclozapine to treat human neuropsychiatric disease
Yasui-Furukori et al. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients
ES2534514T3 (es) Acetato de eslicarbazepina y métodos de uso
WO2008002602A1 (en) Use of n-desmethylclozapine to treat psychosis
Solanki et al. Clozapine: current perspective
HK1116664A (en) Use of n-desmethylclozapine to treat human neuropsychiatric disease
CN101094674A (zh) N-去甲基氯氮平治疗人神经精神疾病的用途
Banham et al. Pharmacodynamics and pharmacokinetics
Meltzer Multiple neurotransmitters involved in antipsychotic drug action
Brunner et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of a selective 5-HT2A antagonist, M100907, following single and multiple oral dosing in healthy volunteers
Rowley et al. Zotepine elevates dopamine in the frontal cortex of freely-moving rats measured by [n vivo microdialysis
Gibler Class Update with New Drug Evaluations: Antipsychotics
Medrano Anxiolytics and Hypnotics
NZ710121B2 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 FEB 2007

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period